Studying clinical of efficiency α-adrenoblockator tamsulozinum at men at of the chronic abacterial prostatitis or chronic pelvic pain syndrome
Keywords:chronic abacterial prostatitis or chronic pelvic pain syndrome, α-adrenoblockator, Tamsin Forte
AbstractThe objective was to evaluate the efficacy of therapy for chronic abacterial prostatitis / chronic pelvic pain syndrome (HAP / CPPS) with Tamsin Forte. Patients and methods. In the dynamics, 34 patients were examined and treated for HAP / CPPS. For monotherapy, Tamsin Forte (tamsulosin) was used, which refers to highly selective α1-adrenoceptor blockers. The age of the examined patients was from 24 to 42 years. The duration of the disease is from 2 to 4 years. All patients underwent a standard urological examination. Results. The use of monotherapy with Tamsin Forte provided a quick clinical effect. Painful sensations were eliminated at the end of a three-month course of treatment in 32 (94.1%) of 34 subjects, dysuric phenomena were stopped in 31 (91.2%). In 7 (87.5%) of 8 patients, improvement of erectile function was noted, premature ejaculation was stopped in 9 (81.8%) of 11 patients. After treatment with Tamsin Forte, the maximum speed of urination was significantly increased. Conclusion. The drug Tamsin Forte is quite effective when used as monotherapy in patients with HAP accompanied by CPPS, as assessed by the doctor (94.2%), and according to the patient's assessment (91.2%). The results obtained make it possible to recommend Tamsin Forte for use in andrological practice.
Barbalis G.A., Nikifororidis G., Liatsikos E.N. Alpha-blockers for the treatment of chronic prostatitis in combinations with antibiotics / J. Urol. – 1998. – Vol. 159. – P. 993–887.
Bjerclund Johansen T.E., Gruneberg R.N., Guibert J. et. al. The Role of Antibiotics in the Treatment of Chronic Prostatitis: A Consensus Statement. Eur. Urol 998; 34: 457–466.
C.R. Chapple Selective α1A-adrenoceptor antagonists in Benign Prostatic Hyperplasia: rationale and clluinical experience. Eur Urol 1996; 29: 129–44.
Caropreso D, Moon T.D. Current Urology Reports 2000, I: 148–154.
Chappee CR, Carter P, Christmas TJ, et. al. A three-month double-blind study of doxazosin as treatment for benign prostatic obstruction. Br J Urol 1994; 74:50–6.
De la Rosette J.J.M.C., Hubregste M.R., Meuleman E.J.H. et. al. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993; (41):301–307.
De la Rossette J.J.M.C.H., Karthaus H. F. M., van Kerrebroeck P.E.V.A. et al. Research in ‘prostatic syndromes’: the use of alfusosin (a new alpha-1 receptor blocking agent) in patients mainly presenting with micturition complains of an irritative nature and confirmed urodynamic abnormalities / Eur. Urol. – 1992. – Vol. 22. – P. 222–227.
Dominique G.J., Human L.G., Hellstrom W.J.G. Hidden microorganisms in «abacterial» prostatitis/prostatodynia. J. Urol 1997; 157 ( 4): 243A.
Drach G.W., Meares E.M., Fair W.R., Stamey T.A. Classification of benign diseases associated with prostatic pain: Prostatitis or pros-tatodynia //J. Urology. – 1978. – Vol. 120. – P. 266.
Webster G.D., Lockhart J.L., Older R.A. The evaluation of bladderneck dysfunction. J. Urol. 1980, vol. 123, p. 196.
Gillenwater JY, Conn RL, Chryslant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in the patients with mild to moderate essential hypertension. J Urol 154:110–15.
Lepor H: Medical management of benign prostatic hyperplasia. Urology 1993; 42:483–401.
Lepor H: Role of long-acting selective alpha 1 blocker in the treatment of benign prostate hyperplasia. Urol Clin North Am 1990; 17:651–659.
Lowe F.C. Safety assessment of terazosin in the treatment of patient with symptomatic benign prostatic hyperpiesia: a combined analysis // Urology, 44(1): 46–51, 1994.
Mehik A., Alas P., Nickel J.C. et al Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study / Urology. – 2003. – Vol. 62. – P. 425–429.
Neal D.E., Moon T.D. Use of terasosin in prostatodynia and validation of symptom score questionnaire / Urology. – 1994. – Vol. 43. – P. 460–465.
Nickel J.C, Sorensson R. Transurethral microwave thermotherapy of nonbacterial prostatitis and prostatodynia: initial experience //Urology, 1994. – Vol. 44. – P. 458–460.
Nickel J. С Prostatitis: Myths and realities //Urology. – 1998. – Vol. 51. – P. 362–366.
Osborn D.E., George N.J.R., Rao Р./ et al. Prostatodynia: physiological characteristics and rationale management with muscle relaxants / Br. J. Urol. – 1987. – Vol. 53. – P. 621–623.
Roehborn CG, Oesterling JE, Lloyd K, et. al. Hytrin community assessement trial. J Urol 1995; 153: 272A.
Stamey T.A. Pathogenesis and treatment of Urinary Tract Infections. Baltimore, Williams and Wilckins; 1980.342–429.
Theodoroy C., Becopoulos T. Prostatitis. Prostate cancer and Prostatic Diseases 1999; 2: 234–240.
Weidner W., Schiefer H.G, Krauss H. et. al. Chronic prostatitis: A through search for etiologically involved microorganisms in 1461 patients. Infection 1991; 19 (3): 119–125.
Дьяков В.В., Говоров А.В. Опыт длительного применения тамсулозина (омник) у больных хроническим простатитом /Урология. – 2002. – No 5. – С. 1–4.
Молочков В.А., Ильин И.И. Хронический уретрогенный простатит. – М., 1998.
Пушкарь Д.Ю., Коско Д.В., Лоран О.Б. и др. Опыт применения финастерида и теразозина у больных с доброкачественной гиперплазией простаты // Урол. и нефрол. – 1995. – No 4. – С. 32–35.
Руководство по андрологии / Под ред. О.Л. Тиктинского. – Л., 1990.
Руководство по урологии / Под ред. Н.А. Лопаткина. – В 3-х томах. – М., 2006.
Пасєчніков С.П. Бухалов Ю.В. Обґрунтування вибору α1-адреноблокатора для купірування гострої затримки сечі. Институт урологии АМН Украины // Здоровье Мужчины. – 2004. – 3 (10). – С. 158–160.
Сивков А.В., Ощепков В.Н., Егоров А.А. Применение α1-адреноблокаторов у больных хроническим простатитом / Consiliummedicum. – 2002. – Т. 4. – С. 385–390.
Юнда И.Ф. Простатиты. – К., 1987.
Copyright (c) 2020 І. І. Горпинченко, Ю. М. Гурженко, В. В. Спиридоненко, В. В. Козлов
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The journal does not require authors of original (primary) research papers to assign the copyright of their published contributions. Authors grant the journal an non-exclusive licence CC BY 4.0 (Creative Commons Attribution 4.0 International License) to using and the first publication of the original in this journal. Copyright of the manuscripts is retained by the authors, after publication authors retain rights to reuse their papers in their future printed work without first requiring permission from the publisher of the journal and share their own published articles.
The journal supports the self-archiving process. Prior to publication in the journal, authors may post a copy of their manuscript in preparation or submitted to the journal in recognized non-commercial preprint servers, public websites. Authors also are encouraged to archive their final author version of the manuscript in their institution's repositories and, if they wish, on their personal websites. Authors should cite the publication reference and DOI number on the first page of any deposited version, and provide a link from it to the URL of the published article on the journal's website.
To facilitate self-archiving of original research papers and help authors fulfil funder and institutional mandates, the journal deposits manuscripts in National Library of Ukraine by V.I. Vernadsky, Scientific periodicals of Ukraine database and different international scintificd database on behalf of authors who opt-in to this free service during submission. The journal provides depositing of articles on official website of the publisher. The full text access to published papers is free.